Dear Eye Care Professional,

The last 24 months have been one of Bausch + Lomb’s busiest periods of innovation. The significant research and development investments we’ve made across our organization have resulted in more than 20 new products that help address some of today’s most pervasive eye health concerns. 

Broadening our Consumer Healthcare Portfolio
One of our most recent innovations is LUMIFY™ (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops. These are the first and only over-the-counter (OTC) eye drops containing low-dose brimonidine tartrate that were developed for the reduction of eye redness due to minor irritation. Backed by six clinical studies, LUMIFY™ has a strong efficacy and safety profile with low risk for rebound redness and 95% symptom improvement seen at one minute and lasting up to eight hours.

For the increasing number of people suffering from dry eye symptoms who are looking for a preservative-free solution, we’ve also recently introduced Soothe® Xtra Protection (XP) Preservative Free lubricant eye drops. Soothe® XP helps restore the essential lipid layer of the tear film and protects against further irritation, and now, with the new preservative free formula, may help more of those with dry eye symptoms, who frequently use moisturizing eye drops.

Building upon our Bausch + Lomb portfolio of eye vitamins, we’re now offering PreserVision® AREDS 2 Formula Chewable vitamins as an alternative for those patients who may have trouble swallowing pills.  PreserVision® AREDS 2 Formula vitamins are the only vitamins that contain the exact levels of six key nutrients recommended by the National Eye Institute, and with the availability of a chewable version, we are able to help more people with moderate to advanced Age-related Macular Degeneration (AMD) reduce their progression by offering a convenient new way to make PreserVision® part of their eye care routine. In the coming weeks, we also look forward to bringing to market new Ocuvite® Blue Light eye vitamins, formulated to help protect eyes from the blue light emitted by digital devices. 

Expanding our Contact Lens Offerings 
In Vision Care, we are in the process of launching Bausch + Lomb ULTRA® for Astigmatism contact lenses in a new cylinder power of -2.75D, which will be available across all power ranges in the portfolio (from +6.00D to -9.00D). This new cylinder power will come with your standard fitting set to help you eliminate the need to special order these lenses and schedule a follow-up appointment for these patients. 

Our Bausch + Lomb ULTRA® contact lenses are also now approved for extended wear for up to seven days on all three modalities. We’re pleased with the continued growth of these lenses as well as our Biotrue® ONEday disposable lenses, which are the fastest growing in their respective segments. Later this summer, we also look forward to providing you more lens parameters for Biotrue® ONEday for Astigmatism.

On our specialty contact lens side of the business, our Zenlens™ scleral lenses and Boston XO® and Boston® XO2 gas permeable materials are now indicated for the treatment of ocular surface disease, including dry eye.  In April, we also launched the Boston® scleral lens case, which is specifically designed to hold larger, scleral lenses (up to 23.5 millimeters in diameter and up to 10.0 millimeters in sagittal depth). 

Finally, we want to thank all those who have contributed to our Bausch + Lomb ONE by ONE Recycling Program. With your and your patients’ contributions, we’ve collected more than 18,000 lbs. of contact lens waste and recycled more than three million units of contact lens materials since first launching the program in November 2016!

Featuring Clinical Data and New Innovations at the American Optometric Association’s Optometry’s Meeting
At Optometry’s Meeting in Denver, we look forward to featuring many of these new innovations. Take a few minutes while you’re there to stop by our booth #1415, create your own before and after picture with new LUMIFY™ redness reliever eye drops and speak with your colleagues and the 

Educational Program on New LUMIFY™ Redness Reliever Eye Drops
We understand that learning from your colleagues is often the best way to understand how you can implement new products into your practice. We invite you to learn more about our new redness reliever eye drops, LUMIFY™, during “A New Advance in Redness Reduction” luncheon on Saturday, June 23 at 12:00 p.m. Paul Karpecki, O.D., FAAO, will discuss LUMIFY™, its mechanism of action and clinical studies, and share his recommendations for how to best incorporate this new Bausch + Lomb product into your practice. 

Scientific Podium Presentations and Posters
Four podium presentations will feature Bausch + Lomb products at AOA this year. This is a testament to the great performance and results eye care professionals and their patients can experience with these innovations.

  • Karpecki, Paul. “LUMIFY™ (Brimonidine Tartrate Ophthalmic Solution, 0.025%) for the Relief of Ocular Redness: Integrated Analysis of Efficacy in Two Clinical Trials.” Friday, June 22 at 4:00 p.m.; AOA Poster #: SA-10, Exhibit Hall
    • A pooled analysis of two clinical studies of brimonidine tartrate ophthalmic solution, 0.025% compared to its vehicle in adult subjects with ocular redness.
  • Karpecki, Paul. “Safety Results from Four Clinical Trials of LUMIFY™ (Brimonidine Tartrate Ophthalmic Solution 0.025%).” Friday, June 22 at 4:30 p.m.; AOA Poster #: SA-11, Exhibit Hall
    • An integrated safety analysis for this α2-adrenergic receptor agonist from four clinical studies.
  • Rah, Marjorie J., Saxon, Jill and William Reindel. “Drivers of Satisfaction with Daily Disposable Multifocal Contact Lenses.” Friday, June 22 at 9 a.m.; AOA Poster #: SA-19, Exhibit Hall 
    • An analysis of patient experiences with Biotrue® ONEday for Presbyopia contact lenses, related to key drivers of patient satisfaction, including sharp, clear vision at near and mid-range distances, ease of transitioning between distances and comfortable wear
  • Rah, Marjorie J. and Scheuer, Catherine A. “Retention and Release of Hyaluronan from Samfilcon A Contact Lenses.” Friday, June 22 at 12:30 p.m.; AOA Poster #: SA-20, Exhibit Hall
    • An evaluation of the adsorption and residence time of hyaluronan (HA) from Biotrue® Multi-purpose Solution with an innovative silicone hydrogel contact lens material, Bausch + Lomb ULTRA® contact lenses 

We’re enthusiastic about the progress we’ve made and for our future as we continue on our mission of helping patients see better to live better. Thank you for your continued support and contributions to the eye health community.

Should you ever have any questions or feedback, please do not hesitate to reach out to our Bausch + Lomb team to share your thoughts. We’d love to hear from you.  

Best Regards,


Joseph Gordon    
President, Consumer Health & Vision Care
Bausch + Lomb 


®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names and/or logos are trademarks of the respective owners.
© 2018 Bausch & Lomb Incorporated. 
MTB.0299.USA.18